Over the last decade, the world of hemophilia has experienced an unprecedented therapeutic advance, thanks to the progress in bioengineering technologies, leading to the introduction of drugs with novel mechanisms of action based on restoring thrombin generation or coagulation factor VIII mimicking. Apart from the bispecific monoclonal antibody emicizumab, already approved for patients with severe hemophilia A with and without inhibitors, novel non-replacement drugs designed to reduce the treatment burden of patients with hemophilia A or B with or without inhibitors are undergoing evaluation in clinical trials. Thanks to their innovative mechanism of action and subcutaneous administration, these drugs promise to provide effective bleeding protection together with improved adherence and improve health-related quality of life for patients with hemophilia. On the other hand, rare thromboembolic events have been reported with some of these drugs and warrant continuous post-marketing surveillance and investigation of predisposing factors, although the overall safety profile of most of these drugs is good. Finally, new challenges need to be faced in the clinical and laboratory monitoring of the hemostatic status in patients treated with these innovative therapies. In this review, we provide an update on the available data on novel non-replacement drugs currently undergoing evaluation in clinical trials for patients with hemophilia.

Updates on Novel Non-Replacement Drugs for Hemophilia / R. Gualtierotti, S. Pasca, A. Ciavarella, S. Arcudi, A. Giachi, I. Garagiola, C. Suffritti, S.M. Siboni, F. Peyvandi. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 15:10(2022 Sep 09), pp. 1183.1-1183.18. [10.3390/ph15101183]

Updates on Novel Non-Replacement Drugs for Hemophilia

R. Gualtierotti
Primo
;
A. Ciavarella;S. Arcudi;A. Giachi;I. Garagiola;C. Suffritti;S.M. Siboni;F. Peyvandi
Ultimo
2022

Abstract

Over the last decade, the world of hemophilia has experienced an unprecedented therapeutic advance, thanks to the progress in bioengineering technologies, leading to the introduction of drugs with novel mechanisms of action based on restoring thrombin generation or coagulation factor VIII mimicking. Apart from the bispecific monoclonal antibody emicizumab, already approved for patients with severe hemophilia A with and without inhibitors, novel non-replacement drugs designed to reduce the treatment burden of patients with hemophilia A or B with or without inhibitors are undergoing evaluation in clinical trials. Thanks to their innovative mechanism of action and subcutaneous administration, these drugs promise to provide effective bleeding protection together with improved adherence and improve health-related quality of life for patients with hemophilia. On the other hand, rare thromboembolic events have been reported with some of these drugs and warrant continuous post-marketing surveillance and investigation of predisposing factors, although the overall safety profile of most of these drugs is good. Finally, new challenges need to be faced in the clinical and laboratory monitoring of the hemostatic status in patients treated with these innovative therapies. In this review, we provide an update on the available data on novel non-replacement drugs currently undergoing evaluation in clinical trials for patients with hemophilia.
hemophilia A; hemophilia B; nonreplacement therapy
Settore MED/09 - Medicina Interna
Settore MED/15 - Malattie del Sangue
9-set-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
pharmaceuticals-15-01183.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 739.18 kB
Formato Adobe PDF
739.18 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/944669
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact